Trial
NCT04705051
Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Sanofi
Collaborators
—
Condition
Congenital Cystic Kidney Disease
Intervention
Venglustat GZ402671
Why stopped
LTS15823 (long-term extension of the EFC15392 study) was stopped after protocol specified interim analysis for futility of the parent EFC15392 study met the prespecified stopping rule based on the primary outcome measure.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-17